Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.

GUIDANCE:

Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.